纵向血浆蛋白质组学揭示可预测肺癌放射性肺炎的免疫血栓特征
该前瞻性研究对57例肺癌患者的267份纵向血浆样本进行高通量蛋白质组学分析,发现免疫血栓轴失调与≥2级放射性肺炎相关,构建的10蛋白模型AUC为0.744(95%CI: 0.622-0.861),优于基线临床模型(AUC=0.679),并在320例外部队列中验证了4蛋白核心(PROZ、SERPINA7、SERPINA6、HAGH)的稳健性。
要点
- 纵向血浆蛋白质组学可识别与≥2级放射性肺炎相关的蛋白轨迹。
- 10蛋白模型预测放射性肺炎的AUC为0.744,优于基线临床模型。
- 4蛋白核心在320例外部队列中验证,校正后仍为独立预测因子。
核心结论
- 系统性免疫血栓特征可跨不同组织学类型和治疗方案准确预测放射性肺炎。
研究设计与样本
- 前瞻性研究,发现队列57例肺癌患者(非小细胞肺癌和小细胞肺癌),采集267份纵向血浆样本进行高通量蛋白质组学分析。
主要发现
- 纵向分析发现免疫血栓轴失调是放射性肺炎的核心驱动因素,血小板激活和Serpin通路显著富集。
- 发生≥2级放射性肺炎的患者呈现关键抗凝和抗炎蛋白进行性下降的「系统性耗竭」特征。
- 10蛋白模型在独立测试集的无偏AUC为0.744(95%CI: 0.622-0.861),优于基线临床模型(AUC=0.679)。
- 外部队列320例验证了4蛋白临床核心(PROZ、SERPINA7、SERPINA6、HAGH)的稳健性,P值范围为10^-8至10^-33。
- 校正平均肺剂量、V20和免疫治疗状态后,该特征仍为显著独立预测因子(P < .05),且与总生存标志物不同。
关键数值与推荐
- 放射性肺炎定义为常见不良事件评价标准v5.0版≥2级。
- 10蛋白模型AUC为0.744(95%CI: 0.622-0.861),基线临床模型AUC为0.679。
- 4蛋白核心外部验证P值范围为10^-8至10^-33。
- 校正平均肺剂量、V20和免疫治疗状态后,特征仍为独立预测因子(P < .05)。
临床怎么用
- 该4蛋白核心可作为临床可移植工具,用于放射性肺炎的早期风险分层和个体化毒性缓解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation pneumonitis (RP) is a dose-limiting toxicity in lung cancer radiation therapy, often poorly predicted by static clinical and dosimetric models. We aimed to identify a robust, blood-based proteomic signature grounded in the longitudinal biological response to radiation to enable accurate, early risk stratification. METHODS AND MATERIALS: We conducted a prospective study using high-throughput plasma proteomics on 267 longitudinal samples from a discovery cohort of 57 patients with lung cancer (non-small cell lung cancer and small cell lung cancer). To ensure statistical rigor and eliminate data leakage, feature selection was performed strictly within a 70% training partition. Linear mixed-effects models and Weighted Gene Co-expression Network Analysis were used to identify protein trajectories associated with symptomatic RP (Common Terminology Criteria for Adverse Events v5.0 grade ≥ 2). An Elastic Net machine learning model was developed and evaluated on an independent test set. The 10-protein signature was subsequently validated via enzyme-linked immunosorbent assay in a large, independent external cohort (n = 320). RESULTS: Longitudinal analysis identified a dysregulated immuno-thrombotic axis as a central driver of RP, characterized by significant enrichment in "Platelet Activation" and "Serpin" pathways. In patients experiencing grade ≥ 2 RP, we observed a "systemic exhaustion" profile marked by the progressive decline of key anticoagulant and anti-inflammatory proteins. The 10-protein model achieved an unbiased area under the curve of 0.744 (95% CI: 0.622-0.861), outperforming a baseline clinical model (area under the curve = 0.679). External validation in 320 patients confirmed the robustness of a 4-protein clinical core (PROZ, SERPINA7, SERPINA6, and HAGH), with Pvalues ranging from 10-8 to 10-33. This signature remained a significant independent predictor (P < .05) after adjusting for mean lung dose, V20, and immunotherapy status, and was distinct from markers of overall survival. CONCLUSIONS: A systemic immuno-thrombotic signature accurately predicts RP across different histologies and treatment regimens. This validated 4-protein core provides a clinically transportable tool for early risk stratification and personalized toxicity mitigation.
引用
- Wu L, Masaki N, Mukohara T, et al. Longitudinal Plasma Proteomics Reveals an Immuno-thrombotic Signature That Predicts Radiation Pneumonitis in Lung Cancer. Int J Radiat Oncol Biol Phys. 2026. PMID: 42176864. doi:10.1016/j.ijrobp.2026.05.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。